Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VP-102 Cantharidin, topical film forming solution, VP-102 - Cantharidin, Topical Film Forming Solution, VP-102- Cantharidin, Film Forming
VP-102 Cantharidin, film forming · 2 trials · 1 indication
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS).
| Arm | Type | Description |
|---|---|---|
| VP-102 | ACTIVE_COMPARATOR | VP-102 is contained within a single-use applicator. The VP-102 applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450 μL of VP-102 (0.7% \[w/v\] cantharidin) solution. |
| Placebo | PLACEBO_COMPARATOR | Placebo is contained within a single-use applicator. The placebo applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450μl of placebo solution with the same color and consistency as VP-102. |
| Name | Type | Description |
|---|---|---|
| VP-102 - Cantharidin, Topical Film Forming Solution | COMBINATION_PRODUCT | VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals. |
| Placebo -Topical Film Forming Solution without VP-102 | COMBINATION_PRODUCT | Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals. |
Inclusion Criteria: To qualify for inclusion in this study, subjects must: 1. Be healthy subjects, at least 2 years of age or older. 2. Consent to having all molluscum lesions treated and the physician must be willing to treat all molluscum lesions initially present. Lesions within 10mm of the eye...